The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer

Video

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Oncotype DX Used for Patients With Breast Cancer to Guide Therapy
Oncotype DX Used for Patients With Breast Cancer to Guide Therapy
Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC
Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC
Ferreyros on Biomarker Access and Physician Autonomy in Community Oncology
Ferreyros on Biomarker Access and Physician Autonomy in Community Oncology
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
Exploring AFM13: Nieto on R/R Lymphoma Treatment Progress
Exploring AFM13: Nieto on R/R Lymphoma Treatment Progress
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
Related Content
Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Targeted Oncology Staff
April 16th 2025
Article

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Jordyn Sava
April 15th 2025
Article

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

Jordyn Sava
April 10th 2025
Article

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Read More

FDA Clears ZEISS INTRABEAM 700 for IORT in Cancer Surgery

FDA Clears ZEISS INTRABEAM 700 for IORT in Cancer Surgery

Jordyn Sava
April 9th 2025
Article

The FDA has granted 501(k) clearance to ZEISS INTRABEAM 700, a robotic-assisted platform designed to enhance intraoperative radiation therapy.

Read More